Niki BioSolutions(NASDAQ) NIKI

Market Cap$3.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-97%
5 Year-98%
1 Year-83%
1 Month-33%
$3.37
-15.75%
-0.63Today
Niki BioSolutions last closing stock price
MetricPriceDate
Last closeUSD 4.002026-10-09
Niki BioSolutions stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-13.04%USD 4.602026-10-02
1 month-33.44%USD 6.012026-09-09
3 month-48.85%USD 7.822026-07-10
Year to date-62.26%USD 10.602025-12-31
1 year-83.12%USD 23.702025-10-09
3 year-78.61%USD 18.702023-10-10
5 year-98.43%USD 255.002021-10-08
Since inception-97.21%USD 143.502018-12-18

Niki BioSolutions Financials at a Glance

Market Cap

$3.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$2.28M

EPS (TTM)

$0.00

P/E Ratio

-1.14

Dividend

$0.00

Beta (Volatility)

0.67 (Low)

Price

$3.37

Volume

12,173.155

Open

$3.84

Previous Close

$4.00

Daily Range

$3.20 - $3.84

52-Week Range

$3.20 - $17.60

Estimated Earnings Date

N/A

NIKI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Niki BioSolutions

Niki BioSolutions, Inc. is a biopharmaceutical company formed from the merger of Aptorum Group and DiamiR Biosciences. The company is dedicated to developing and commercializing a diverse portfolio of therapeutic and diagnostic assets, focusing on unmet medical needs in oncology and infectious diseases.

Products and Services
  • Therapeutics for oncology and infectious diseases
  • Innovative blood-based diagnostic tests for brain health
  • Development of diagnostic assets targeting various health conditions
Growth Outlook
  • Strong focus on unmet medical needs positions the company for future growth
  • Recent investments in R&D indicate commitment to innovation
  • Potential market expansion in the biopharmaceutical sector
Financial Highlights
  • Recent quarterly net income of -$307,495 reflects ongoing investment in R&D
  • Cash and short-term investments totaled $3,452,891 as of Q4 2025
  • Market capitalization stands at approximately $39.25 million
Niki BioSolutions, Inc. operates in the biotechnology industry, focusing on innovative solutions for critical health challenges. The company’s commitment to research and development is evident in its financials, with significant investments aimed at advancing its therapeutic and diagnostic offerings. The recent quarterly results indicate a strategic focus on long-term growth, despite current net losses. The company maintains a solid cash position, which supports ongoing operations and development initiatives. With a market capitalization of approximately $39.25 million, Niki BioSolutions is positioned to leverage its unique assets in a growing biopharmaceutical market.
AI Generated • Sep 24, 2026

Industry

Biotechnology

Sector

Health Care

Employees

2

CEO

Ian Huen, CFA

Website

www.aptorumgroup.com

Headquarters

Princeton, NJ 08540, US

NIKI Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-5.94%

Return on Capital

-6.83%

Return on Assets

-7.29%

Earnings Yield

-87.72%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

814.40K

Volume

12.17K

Avg. Volume

158.82K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$402.77K

EBITDA

-$1.54M

Operating Cash Flow

-$3.26M

Capital Expenditure

-$48.00

Free Cash Flow

-$3.26M

Cash & ST Invst.

$3.45M

Total Debt

$3.44M

Niki BioSolutions Performance Analysis

Niki BioSolutions annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 1,295,889-15.9%
20232023-12-31USD 431,378-66.7%
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Niki BioSolutions sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Niki BioSolutions annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -27.45-61.6%
20232023-12-31USD -6.25-77.2%
20242024-12-31USD -7.8325.3%
20252025-12-31USD -1.85-76.3%
Niki BioSolutions sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q22025-06-30N/A
Q32025-09-30-37.1%
Q42025-12-3150.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$3.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.26M

N/A

Employees

1

N/A

Net Income

-$307.50K

+88.4%

EBITDA

-$825.13K

+64.7%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$3.45M

+340.9%

Total Debt

$3.44M

+1.9%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$3.44M

+1237.2%

Return on Assets

-7.29%

N/A

Return on Invested Capital

-2.86%

N/A

Free Cash Flow

-$535.26K

+91.4%

Operating Cash Flow

-$535.26K

+91.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,811.54+0.01%
^DJIDJI
$51,654.95+0.01%
^IXICNASDAQ
$27,366.17+0.01%
BTCBitcoin
$83,785.00+0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
BITOProShares Trust - ProShares Bitcoin ETF
$11.02+0.14%
ONDSOndas
$6.76+0.47%
SPCXSpace Exploration Technologies
$164.15+0.97%
NOKNokia
$9.93-4.20%

Questions About NIKI

What is the current price of Niki BioSolutions?

Niki BioSolutions is trading at $3.37 per share.

What is the 52-week range for Niki BioSolutions?

Over the past 52 weeks, Niki BioSolutions has traded between $3.20 and $17.60.

How much debt does Niki BioSolutions have?

As of the most recent reporting period, Niki BioSolutions reported total debt of $3.52M.

How much cash does Niki BioSolutions have on hand?

Niki BioSolutions reported $3.45M in cash and cash equivalents in its most recent financial results.

What is Niki BioSolutions’s dividend yield?

Niki BioSolutions does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services